Acasti Pharma, Inc. - Common Stock (ACST)
$3.37
0.00 (0.00%)
ACST Stock Quote Delayed 30 Minutes
Acasti Pharma Stock Is Bleeding Both Value and Credibility
Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
150.35M
PE Ratio
-3.92
EPS
-0.86
Volume (Avg. Vol.)
Day's Range
-
52-Week Range
$2.13 - $3.60
Dividend & Yield
N/A (N/A)
ACST Stock Predictions, Articles, and Acasti Pharma, Inc. - Common Stock News
The Future Doesn’t Look Too Bright For Acasti Pharma Stock
Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed.
Acasti’s Losing Drug and ACST Stock Are Not for Weak Hearts
Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock.
Does Acasti Stock Have a Future?
Acasti got some bad news recently from the FDA regarding its main drug candidate. And this news could make it tough for ACST stock to recover.
The Future of ACST Stock Is on Hold
ACST stock was already a tough gamble due to the competition for omega-3-based drugs. However, without FDA approval, the underlying pharmaceutical is merely a gamble.
Acasti Pharma Stock Could Soar Above $3 Soon
When Acasti posts Phase 3 trial results, ACST stock could re-visit recent highs. Here's why you should pay attention to the stock now.
Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today
Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices?
10 Pharmaceuticals Stocks to Sell Now
This week, the overall grades of 10 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
26 Pharmaceuticals Stocks to Sell Now
The ratings of 26 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Hottest Manufacturing Stocks Now – ARLZ LAKE ACRX COLL
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
5 Best Stocks Under $5 This Week
It was a volatile, tough week on Wall Street, but Acasti Pharma, Myos Corp,, Enphase Energy, Actinium Pharmaceuticals, and Innovative Solutions & Support made investing look easy.
Want to Invest in Biotech Stocks? Learn the Rules First.
Even in the good conditions of the biotech market today, investors should do due diligence and find reliable sources when picking biotech stocks.
